


### Electronic Annex 1. Study plan (Gantt chart)



**Electronic Annex 2. Cases reported by participating countries and countries' estimated coverage at the time of data reporting**

Countries	Cases enrolled N	Centres N	Estimated coverage <sup>Ω</sup>
Argentina	30	1	12.5%* (Buenos Aires)
Australia	2	2	20% <sup>§</sup> (New South Wales)
Belarus	3	1	10%* (Minsk)
Belgium	1	1	100%* (Namur)
Brazil	66	6	80% <sup>§</sup> (Rio Grande do Sul & Goiás) 40% <sup>§</sup> (Bahia & São Paulo)
Canada	1	1	5% <sup>§</sup> (Ontario)
Chile	70	47	100% <sup>^</sup> (Whole country)
China	4	2	100%* (Wenzhou and Luzhou)
Colombia	2	1	10% <sup>^</sup> (Whole country)
France	10	6	50% <sup>^</sup> (Whole country)
Greece	1	1	80% <sup>#</sup> (Northern Region) 20% <sup>^</sup> (Whole country)
Guinea Republic	2	1	100%* (Conakry) 20% <sup>^</sup> (Whole country)
Honduras	23	7	100% <sup>^</sup> (Whole country)
India	37	3	80%* (New Delhi) 20%* (Nagpur) 10%* (Mumbai)
Italy	58	10	80% <sup>^</sup> (Whole country)
Lithuania	27	2	100%* (Vilnius and Klaipedia)
Mexico	17	9	30% <sup>^</sup> (Whole country)
Netherlands	1	1	100% <sup>^</sup> (Whole country)
Niger	1	1	100% <sup>^</sup> (Whole country)
Oman	13	4	100% <sup>^</sup> (Whole country)
Panama	8	1	100% <sup>^</sup> (Whole country)
Paraguay	80	17	100% <sup>^</sup> (Whole country)
Peru	32	2	80% <sup>^</sup> (Whole country)
Portugal	2	2	100%* (Vila Nova de Gaia and Espinho)
Romania	23	2	100%* (Craiova) 10% <sup>#</sup> (South Western Region) 100%* (Timisoara) 10.5% <sup>#</sup> (Western Region)
Russian Federation	65	3	100%** (Moscow, Arkhangelsk & Volgograd)
Serbia	6	1	100% <sup>^</sup> (Whole country)
Singapore	24	2	75% <sup>^</sup> (Whole country)
Slovakia	3	1	100% <sup>^</sup> (Whole country)
South Africa	15	7	25% <sup>#</sup> (Western Cape Province)
Spain	24	8	70% <sup>^</sup> (Whole country)
Switzerland	1	1	100% <sup>#</sup> (Vaud Canton)
United Kingdom	64	2	25%* (London)
USA	51	16	375 <sup>§</sup> (Virginia State)
<b>TOTAL= 34</b>	<b>TOTAL= 767</b>	<b>TOTAL= 172</b>	<b>RANGE (5%-100%)</b>

Legend: <sup>Ω</sup> Countries' estimate of the national/subnational coverage of the TB/COVID-19 (TB: tuberculosis; COVID-19: acute respiratory syndrome coronavirus 2 (SARS-CoV-2)) cases at the time of data reporting; \*estimated coverage in the metropolitan area(s) reporting; <sup>§</sup> estimated coverage in the state(s) reporting; <sup>#</sup> estimated coverage in the region/province/canton reporting; \*\*estimated coverage in the 3 Oblasts reporting; <sup>^</sup> estimated coverage compared to cases reported in the whole country

**Electronic Annex 3: Comorbidities prior to COVID-19 diagnosis in 767 patients of the TB/COVID-19 cohort**

<b>PATIENTS WITH &gt;=1 COMORBIDITIES</b>	<b>ALIVE (N=343) n(%)</b>	<b>DEAD (N=73) n(%)</b>
<b>CARDIOVASCULAR DISEASE</b>		
Hypertension	81 (23.6)	27 (37.0)
Congestive Heart Failure	16 (4.7)	12 (16.4)
Ischemic heart disease	14 (4.1)	14 (19.2)
Stroke	6 (1.7)	9 (12.3)
Atrial fibrillation	4 (1.2)	4 (5.5)
Other Cardiovascular disease	10 (2.9)	4 (5.5)
<b>ENDOCRINE DISEASE</b>		
Diabetes Mellitus	125 (36.4)	32 (43.8)
Hypothyroidism	6 (1.7)	3 (4.1)
<b>IMMUNOCOMPROMISING CONDITIONS</b>		
HIV	68 (19.8)	12 (16.4)
Autoimmune Disease	18 (5.2)	3 (4.1)
Organ Transplant	4 (1.2)	2 (2.7)
<b>RESPIRATORY DISEASE</b>		
Other Lung Disease	56 (16.3)	21 (28.8)
Asthma	18 (5.2)	6 (8.2)
<b>LIVER DISEASE</b>		
	50 (14.6)	10 (13.7)
<b>RENAL DISEASE</b>		
	38 (11.1)	15 (20.5)
<b>CANCER</b>		
	23 (6.7)	11 (15.1)
<b>PSYCHIATRIC DISORDERS</b>		
	18 (5.2)	8 (11.0)
<b>NUTRITION DISORDERS</b>		
	5 (1.5)	3 (4.1)
<b>OTHER DISEASES</b>		
	8 (2.3)	3 (4.1)

Legend: TB: tuberculosis; COVID-19: acute respiratory syndrome coronavirus 2 (SARS-CoV-2)